ストックスクリーナーアプリを入手
1.80
1.64%
-0.03
アフターアワーズ：
1.82
0.02
+1.11%
前日終値:
$1.83
開ける：
$1.84
24時間の取引高:
1.00M
Relative Volume:
0.34
時価総額：
$179.60M
収益：
-
当期純損益:
$-37.34M
株価収益率:
-1.3235
EPS:
-1.36
ネットキャッシュフロー:
$-36.91M
1週間 パフォーマンス:
+1.69%
1か月 パフォーマンス:
-2.70%
6か月 パフォーマンス:
+78.22%
1年 パフォーマンス:
+55.17%
1日の値動き範囲:
$1.78
$1.86
1週間の範囲:
$1.75
$1.94
52週間の値動き範囲:
$0.772
$2.2691
Sellas Life Sciences Group Inc Stock (SLS) Company Profile
名前
Sellas Life Sciences Group Inc
セクター
電話
(646) 200-5278
住所
7 TIMES SQUARE, NEW YORK, NY
SLS を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SLS
Sellas Life Sciences Group Inc
|
1.80 | 182.59M | 0 | -37.34M | -36.91M | -1.36 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Sellas Life Sciences Group Inc Stock (SLS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2021-07-21 | 開始されました | Cantor Fitzgerald | Overweight |
| 2018-11-01 | 開始されました | Oppenheimer | Outperform |
| 2018-04-02 | 開始されました | H.C. Wainwright | Buy |
| 2018-03-19 | アップグレード | Maxim Group | Hold → Buy |
Sellas Life Sciences Group Inc (SLS) 最新ニュース
Does SELLAS Life Sciences Group Inc. stock perform well during market downturnsBuild a portfolio that outperforms the market - jammulinksnews.com
Should I hold or sell SELLAS Life Sciences Group Inc. stock in 2025Achieve breakthrough financial results today - jammulinksnews.com
How strong is SELLAS Life Sciences Group Inc. company’s balance sheetFree Technical Analysis Support - jammulinksnews.com
What are analysts’ price targets for SELLAS Life Sciences Group Inc. in the next 12 monthsRobust investment performance - jammulinksnews.com
What analysts say about SELLAS Life Sciences Group Inc. stockExplosive portfolio gains - Autocar Professional
SELLAS Life Sciences Group Inc. Stock Analysis and ForecastTriple-digit profit margins - PrintWeekIndia
What institutions are buying SELLAS Life Sciences Group Inc. stock nowStrong return on assets - jammulinksnews.com
What drives SELLAS Life Sciences Group Inc. stock priceFree Stock Market Real-Time Monitoring - Autocar Professional
Is SELLAS Life Sciences Group Inc. a good long term investmentTurbocharged investment results - jammulinksnews.com
What drives USEA stock priceMassive wealth growth - jammulinksnews.com
What makes SELLAS Life Sciences Group Inc. stock attractive to long term investorsMomentum Swing Watchlist - beatles.ru
SELLAS Life Sciences Group (NASDAQ:SLS) Stock Price Expected to Rise, Maxim Group Analyst Says - Defense World
Cancer Pipeline Milestones Coming Fast as Regulators Revisit Research Priorities - Finansavisen
Sellas Life Sciences shares fall 1.58% premarket after meeting primary endpoints in Phase 2 trial. - AInvest
SELLAS Meets All Primary Endpoints in Phase 2 Trial of - GlobeNewswire
Sellas Targets Tambiciclib To Adverse-Risk Frontline AML Patients After Phase II Success - insights.citeline.com
What makes SELLAS Life Sciences Group Inc. stock price move sharplyReal Time Breakout Tracking - Newser
How SELLAS Life Sciences Group Inc. stock performs during market volatilityHigh Yield Opportunities - Newser
Sellas Flat on Trial Success - Baystreet.ca
Sellas Life Sciences Meets Primary Endpoints in Mid-Stage SLS009 Trial - MarketScreener
SELLAS gains on mid-stage trial win for leukemia drug (SLS) - Seeking Alpha
SELLAS' Phase 2 Study Of SLS009 In Acute Myeloid Leukemia Meets All Primary Goals - Nasdaq
Why SELLAS Life Sciences Group Inc. stock attracts strong analyst attentionSolid Return Trade Selections - Newser
SELLAS Life Sciences Group Reports Positive Phase 2 Trial Results for SLS009 in Relapsed/Refractory Acute Myeloid Leukemia - Nasdaq
SELLAS Meets All Primary Endpoints in Phase 2 Trial of SLS009 in r/r AML and Receives FDA Guidance to Advance into First-Line Therapy Study - The Manila Times
Sellas Life Sciences Group Inc (SLS) 財務データ
収益
当期純利益
現金流量
EPS
0.97%
0.22%
大文字化:
|
ボリューム (24 時間):